Isomorphic Labs raised $2.1 billion in its second round of outside capital, a B round that Bloomberg reported on May 12 and Forbes and Yahoo Taiwan also published on May 13. [1, 2, 3]
The funding was led by Thrive Capital, while Bloomberg named Alphabet, Abu Dhabi’s MGX, Singapore’s Temasek and the UK’s Sovereign AI fund among the investors. Yahoo Taiwan said Alphabet and GV also took part and singled out the UK Sovereign AI Fund. [1, 3]
Isomorphic Labs is an Alphabet-founded company that uses AI to speed up drug development. Forbes said the new financing follows the company’s first outside funding round of $600 million last year and was done at an undisclosed valuation. [1, 2]
Max Jaderberg said, “We’re aiming to redefine the way we create new medicines,” and called the latest backing “a lot of validation of what we’ve been building out the past four-and-a-half, almost five, years.” [2]
Yahoo Taiwan said the company plans to use the money to expand its drug design engine, IsoDDE, and accelerate therapeutic programs toward clinical trials. Ruth Porat said the use of AI in health care offers “far-reaching opportunities” and that the funding will help speed important medical interventions to market, while Demis Hassabis said the round showed top global investors strongly backed its “AI-first” drug design and development strategy. [3]
Forbes also reported that Isomorphic Labs has partnerships with Novartis and Eli Lilly that could be worth up to $3 billion combined. [2]
